320 related articles for article (PubMed ID: 22593043)
1. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response.
Zhong Y; Zhang F; Sun Z; Zhou W; Li ZY; You QD; Guo QL; Hu R
Mol Carcinog; 2013 Oct; 52(10):824-34. PubMed ID: 22593043
[TBL] [Abstract][Full Text] [Related]
2. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway.
Xu X; Zhang Y; Li W; Miao H; Zhang H; Zhou Y; Li Z; You Q; Zhao L; Guo Q
Biochem Pharmacol; 2014 Nov; 92(2):220-34. PubMed ID: 25264278
[TBL] [Abstract][Full Text] [Related]
3. Wogonin-enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by suppression Nrf2-mediated signaling in HepG2 cells.
Qian C; Wang Y; Zhong Y; Tang J; Zhang J; Li Z; Wang Q; Hu R
Free Radic Res; 2014 May; 48(5):607-21. PubMed ID: 24666416
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment.
Venkatraman G; Benesch MG; Tang X; Dewald J; McMullen TP; Brindley DN
FASEB J; 2015 Mar; 29(3):772-85. PubMed ID: 25398768
[TBL] [Abstract][Full Text] [Related]
6. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway.
Huang KF; Zhang GD; Huang YQ; Diao Y
Int Immunopharmacol; 2012 Feb; 12(2):334-41. PubMed ID: 22182776
[TBL] [Abstract][Full Text] [Related]
7. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
8. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
9. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway.
Liu WH; Chang LS
Int J Biochem Cell Biol; 2011 Dec; 43(12):1708-19. PubMed ID: 21854868
[TBL] [Abstract][Full Text] [Related]
10. Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation.
Xu X; Zhang X; Zhang Y; Yang L; Liu Y; Huang S; Lu L; Kong L; Li Z; Guo Q; Zhao L
Sci Rep; 2017 Feb; 7():39950. PubMed ID: 28150717
[TBL] [Abstract][Full Text] [Related]
11. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines.
Gao HL; Xia YZ; Zhang YL; Yang L; Kong LY
Phytomedicine; 2019 May; 58():152885. PubMed ID: 31009836
[TBL] [Abstract][Full Text] [Related]
12. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
13. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
14. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway.
Gao AM; Ke ZP; Shi F; Sun GC; Chen H
Chem Biol Interact; 2013 Oct; 206(1):100-8. PubMed ID: 23994249
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
16. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.
Scherbakov AM; Lobanova YS; Andreeva OE; Shatskaya VA; Krasil'nikov MA
Biosci Rep; 2011 Apr; 31(2):137-43. PubMed ID: 20662767
[TBL] [Abstract][Full Text] [Related]
17. Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression.
Chen B; Zhang Y; Wang Y; Rao J; Jiang X; Xu Z
J Steroid Biochem Mol Biol; 2014 Sep; 143():11-8. PubMed ID: 24486718
[TBL] [Abstract][Full Text] [Related]
18. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
19. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
20. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
